Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting
- SGT-001 Cardiac and Skeletal Muscle Microdystrophin Expression and Functional Efficacy in Preclinical Models of DMD
Abstract Number: 39
Monday, April 29th at 11:00 a.m. ET
- Multiparameter In Vivo Screen of
AncAAV Librariesin Muscle for Potency, Specificity and Impact of Disease State
Abstract Number: 376
Tuesday, April 30th at 4:00 p.m. ET
- Identification of Novel Muscle Specific Promoters and AAV Gene Expression in Skeletal and Cardiac Muscles
Abstract Number: 822
Wednesday, May 1st at 5:00-6:00 p.m. ET
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.
Source: Solid Biosciences Inc.